Tissue transplantation

August 1997
Clinical & Investigative Medicine;Aug97 Supplement, Vol. 20, pS104
Academic Journal
Presents an abstract of the research manuscript `Effect of phospholipid hydrogenation on the biodisposition of liposomal tacrolimus,' by V. McAlister et al.


Related Articles

  • Collagen hypersensitivity Tx option. Guttman, Cheryl // Cosmetic Surgery Times;Jan/Feb2002, Vol. 5 Issue 1, p41 

    Focuses on the modality of topical tacrolimus for the management of bovine collagen hypersensitivity among patients in Dallas, Texas. Distinction of Brent R. Moody on the development of the concept; Details of the treatment and its augmentation; Response of patients on the treatment.

  • Topical tacrolimus ointment challenges steroids. Magee, Jim // Dermatology Times;Feb2001, Vol. 22 Issue 2, p17 

    Reports that data from studies conducted in the United States and Europe indicates that topical tacrolimus ointment (Protopic) is safe and effective for the treatment of atopic dermatitis (AD). Related presentations made during the ninth annual congress of the European Academy of Dermatology...

  • Tacrolimus may resolve bovine collagen hypersensitivity. Guttman, Cheryl // Dermatology Times;Jan2002, Vol. 23 Issue 1, p47 

    Reports on the potential of topical tacrolimus as a useful modality for management of bovine collagen hypersensitivity. Case example of a 45-year-old with bovine collagen allergy treated with topical tacrolimus; Reason behind decision to try topical tacrolimus to treat bovine collagen allergy.

  • Prevention of antigen-induced bronchial hyperreactivity and airway inflammation in sensitized guinea-pigs by tacrolimus. Lapa, J. R.; Silva, E.; Ruffie, C.; Lefort, J.; Nahori, M-A.; Vargaftig, B. B.; Pretolani, M. // Mediators of Inflammation;Feb99, Vol. 8 Issue 1, p17 

    WE examined the effect of the immunosuppressive agent, tacrolimus (FK506), on antigen-induced bronchial hyperreactivity to acetylcholine and leukocyte infiltration into the airways of ovalbumin-challenged guinea-pigs. Subcutaneous injection of 0.5 mg/kg of FK506, 1 h before and 5 h after...

  • Covariate Effects on the Apparent Clearance of Tacrolimus in Paediatric Liver Transplant Patients Undergoing Conversion Therapy. Sanchez, M.J.G.; Manzanares, C.; Santos-Buelga, D.; Blázquez, A.; Manzanares, J.; Urruzuno, P.; Medina, E. // Clinical Pharmacokinetics;2001, Vol. 40 Issue 1, p63 

    Objective: To analyse the influence of covariates on the apparent clearance (CL) of tacrolimus in paediatric liver transplant recipients being converted from cyclosporin to tacrolimus. Design: Retrospective modelling study. Patients and participants: 18 children, 13 girls and 5 boys, aged 4...

  • Wide Range of HQL Benefits Seen with Transplant.  // Kidney;Sep/Oct98, Vol. 7 Issue 5, p215 

    Discusses the abstract of a study entitled 'Assessment of health-related quality of life in kidney transplant patients receiving tacrolimus (FK506)-based versus cyclosporine-based immunosuppression,' by C.F. Shield III, M.M. McGrath and T.F. Goss, published in the 1998 issue of 'Transplantation.'

  • Tacrolimus Lowers Cholesterol, LDL, and Apo B.  // Kidney;Sep/Oct98, Vol. 7 Issue 5, p222 

    Discusses the abstract of a study entitled 'Effects of tacrolimus on hyperlipidemia after successful renal transplantation,' by T.R. McCune, L.R. Thacker II, T.G. Peters and others, published in the 1998 issue of 'Transplantation.'

  • Growth and renal function after steroid-free tacrolimus-based immunosuppression in children with renal transplants. Ellis, D. // Pediatric Nephrology;Jul2000, Vol. 14 Issue 7, p689 

    Steroid withdrawal after renal transplantation and cyclosporine-based immunosuppression enhances growth in children, but this practice is not widely employed because of a 50%–60% rate of rejection, graft dysfunction, or graft loss. The current study evaluates growth and renal function...

  • Tacrolimus: review of pharmacokinetics, pharmacodynamics, and pharmacogenetics to facilitate practitioners' understanding and offer strategies for educating patients and promoting adherence. Vicari-Christensen, Michele; Repper, Suzanne; Basile, Sharon; Young, Danella // Progress in Transplantation;Sep2009, Vol. 19 Issue 3, p277 

    Kidney transplantation requires lifelong immunosuppression with agents that prevent allograft rejection. Immunosuppressive regimens typically include a steroid, an immune modulator (eg, azathioprine, mycophenolate mofetil, or mycophenolate sodium), and a calcineurin inhibitor, either...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics